Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Junggu
Clinical trial register · South Korea

Clinical Trials in Junggu, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3365 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:17 UTC
3365
Studies in scope
all four open statuses
1831
Recruiting now
open to new participants
500
Lead sponsors
across recruiting studies
Top sites
Seoul 2821 Daegu 554 Seongnam-si 493 Busan 468 Goyang-si 396
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company8 Bristol-Myers Squibb4 AstraZeneca4 Merck Sharp & Dohme LLC3 Pfizer3
Site location
Seoul2821 Daegu554 Seongnam-si493 Busan468 Goyang-si396
All 252 locations
Target enrolment
to

Trials with a site in Junggu

37 of 3365 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Not yet open
Eli Lilly and Company
Phase 3
170
Bucheon-si, Deagu, Junggu, Seongnam, Seoul
2026-09
Recruiting
Eli Lilly and Company
Phase 3
2,001
Ansan-si, Anyang-si, Busan, Guri-si, Gwangju, Junggu, Seogu, Seongnam
2026-08-26
Recruiting
AstraZeneca
Phase 3
7,000
Anyang-si, Busan, Cheonan-si, Daejeon, Goyang-si, Guri-si, Junggu, Seoul
2026-08-21
Recruiting
AstraZeneca
Phase 3
600
Bucheon-si, Gyeonggi-do, Jongno-gu, Junggu, Seoul
2026-07-08
Recruiting
Bristol-Myers Squibb
Phase 3
750
Busan, Seoul, Deagu, Junggu
2026-03-12
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
DrugsVepugratinib·Pembrolizumab
Eli Lilly and Company
Phase 3
450
Goyang-si, Junggu, Namdong-gu, Seongnam, Seoul
2025-12-12
Recruiting
Eli Lilly and Company
Phase 3
1,100
Anyang-si, Busan, Cheongju-si, Guri-si, Incheon, Junggu, Namdong-gu, Seogu
2025-10-16
Recruiting
Eli Lilly and Company
Phase 3
1,100
Busan, Cheongju-si, Guri-si, Junggu, Namdong-gu, Seogu, Seongnam, Seoul
2025-10-15
Recruiting
Eli Lilly and Company
Phase 3
1,000
Anyang-si, Bucheon-si, Busan, Gwangju, Junggu, Seoul
2025-09-30
Recruiting
Pfizer
Phase 3
1,000
Goyang-si, Seongnam, Seoul, Junggu
2025-09-28
Recruiting
GlaxoSmithKline
Phase 2
220
Junggu
2025-08-14
Recruiting
Takeda
Phase 2
88
Junggu, Suwon, Seoul
2025-05-06
Recruiting
BeOne Medicines
Phase 3
250
Seogu, Junggu, IlsandongGu GoyangSi, HwasunGun, GangnamGu, SeochoGu, Seoul
2025-04-10
Recruiting
Pfizer
Phase 3
900
Hwasun, Goyang-si, Seoul, Daegu, Junggu
2024-10-22
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
Goyang-si, Seongnam, Suwon, Pusan, Cheongju-si, Busan, Daegu, Junggu
2024-06-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Bupyeong-gu, Hwasun, Suwon, Yangsan, Daegu, Junggu, Incheon, Seoul
2024-05-24
Active, closed
EverEx Inc.
Not applicable
216
Goyang-si, Guri-si, Gyeonggi-do, Seongnam-si, Junggu, Dongjak, Gangdong, Seocho
2024-04-26
Active, closed
Bristol-Myers Squibb
Phase 2
310
Songpa-gu, Gwangjingu, Incheon, Junggu
2024-03-20
Active, closed
Gilead Sciences
Phase 2
176
Seodaemun-Gu, Busan, Daegu, Junggu, Seoul
2023-12-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Hwasun, Goyang-si, Seongnam, Suwon, Yangsan, Cheongju-si, Busan, Junggu
2023-11-12
Active, closed
GlaxoSmithKline
Phase 4
50
Incheon, Junggu, Kyungki-do, Seongnam-si Gyeonggi-do, Seoul
2023-11-10
Active, closed
Bristol-Myers Squibb
Phase 2
227
Pusan, Daejeon, Gwangju, Seongnam, Junggu, Seoul, Daegu
2023-11-07
Recruiting
Ipsen
Phase 3
276
Bucheon-si, Busan, Daegu, Daejeon, Goyang-si, Gyeonggi-do, Incheon, Junggu
2023-08-31
Active, closed
AstraZeneca
Phase 3
94
Cheongju-si, Junggu, Seoul
2023-04-05
Recruiting
Eli Lilly and Company
Phase 3
595
Busan, Cheonan-si, Daejeon, Incheon, Jeonju, Junggu, Seongnam-si, Seoul
2023-02-27
Active, closed
Bristol-Myers Squibb
Phase 2/3
230
Hwasun Gun, Seoul, Junggu
2022-12-14
Active, closed
Viatris Innovation GmbH
Phase 3
470
Busan, Daegu, Junggu, Seoul
2022-12-13
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugDonanemab
Eli Lilly and Company
Phase 3
1,500
Busan, Guri-si, Gwangju, Incheon, Junggu, Namdong-gu, Seongnam, Seongnam-si
2022-10-10
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
410
Pusan, Junggu, Seoul
2022-08-23
Active, closed
AstraZeneca
Phase 3
760
Busan, Daegu, Goyang-si, Junggu, Seoul
2022-03-28
Active, closed
Pfizer
Phase 3
854
Namdong-gu, Hwasun Gun, Seongnam, Busan, Seoul, Daegu, Junggu
2022-03-25
Active, closed
Mirati Therapeutics Inc.
Phase 3
453
Busan, Cheongju-si, Daegu, Hwasun-gun, Incheon, Junggu, Seongnam-si, Seoul
2021-02-23
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Busan, Cheongju-si, Daegu, Goyang-si, Junggu, Seoul, Suwon
2020-12-02
Active, closed
Exelixis
Phase 3
575
Junggu, Goyang-si, Seongnam-si, Hwasun, Busan, Daegu, Gwangju, Seoul
2020-10-19
Active, closed
AbbVie
Phase 3
527
Junggu, 서구, Seoul
2020-09-30
Active, closed
AbbVie
Phase 3
1,629
Daegu, Junggu, Gwangju, Seongdong-gu, Seoul
2015-12-01
Active, closed
MedImmune LLC
Phase 2
433
Busan, Junggu, Seongnam-si, Seoul
2015-10-19
Rows per page Showing 1–37 of 37
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-south-korea/city/junggu

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,365 studies in total at the last sync on 11 Oct 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 37 of those studies with a site in Junggu.

How many clinical trials are recruiting in Junggu?

18 of the 37 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:17 UTC sync. A further 1 have not yet opened recruitment, 18 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Junggu), 37 studies
PhaseStudiesRecruitingShare
Phase 3271573%
Phase 26216.2%
Phase 2/3215.4%
Not applicable102.7%
Phase 4102.7%

Most active sponsors

Lead sponsors with the most studies (Junggu)
Lead sponsorStudiesRecruiting
Eli Lilly and Company86
AstraZeneca42
Bristol-Myers Squibb41
Merck Sharp & Dohme LLC31
Pfizer32
AbbVie20
GlaxoSmithKline21
Mirati Therapeutics Inc.21
BeOne Medicines11
EverEx Inc.10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.